| Stereochemistry | RACEMIC |
| Molecular Formula | C15H23NO2 |
| Molecular Weight | 249.3486 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CNCC(C1=CC=C(O)C=C1)C2(O)CCCCC2
InChI
InChIKey=MMSWXJSQCAEDLK-UHFFFAOYSA-N
InChI=1S/C15H23NO2/c1-16-11-14(12-5-7-13(17)8-6-12)15(18)9-3-2-4-10-15/h5-8,14,16-18H,2-4,9-11H2,1H3
| Molecular Formula | C15H23NO2 |
| Molecular Weight | 249.3486 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
N,O-Didesmethylvenlafaxine is a metabolite of venlafaxine, an antidepressant of the serotonin-norepinephrine reuptake inhibitor (SNRI) class. In humans, venlafaxine is biotransformed for the most part by CYP2D6 and CYP2C19 isoenzymes to its major metabolite O-desmethylvenlafaxine, and in parallel to N-desmethylvenlafaxine and N,O-didesmethylvenlafaxine. It was shown, that CYP2D6 genotype influenced the O-demethylation whereas CYP2C19 influenced the N-demethylation of venlafaxine and its metabolites.
Approval Year
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
